Maria Inês Canha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Inês Canha has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
João Coimbra
Gastroenterology Department Centro Hospitalar Universitário de Lisboa Central Lisbon Portugal
4 shared publicationsGonçalo Ramos
Gastroenterology Department Centro Hospitalar Universitário de Lisboa Central Lisbon Portugal
3 shared publicationsRita Prata
Gastroenterology Department Centro Hospitalar Universitário de Lisboa Central Lisbon Portugal
3 shared publicationsMarta Viúla Ramos
Gastroenterology Department of Centro Hospitalar Universitário de Lisboa Central, EPE, Lisbon, Portugal
2 shared publicationsPedro Lages Martins
Gastroenterology Department of Centro Hospitalar Universitário de Lisboa Central, EPE, Lisbon, Portugal
2 shared publications- Ana Rodrigues
Department of Medical Oncology, Instituto Português de Oncologia do Porto, 4200-162 Porto, Portugal
1 shared publication
Latest Publications
- Open Access
- 30 November 2023
- Published by Indonesian Society of Pediatric Gastroenterology, Hepatology, and Nutrition in Archives of Pediatric Gastroenterology, Hepatology, and Nutrition
- Vol. 2 (4) , 24-9
Endoscopic Retrograde Cholangiopancreatography with an Ultra-Slim Forward-Viewing Gastroscope in a 3.8 kg Infant: A Case-Report
Background: Experience with pediatric endoscopic retrograde cholangiopancreatography (ERCP), particularly in infants, is limited. The lower incidence of biliopancreatic disorders in infants and the discontinuation of pediatric duodenoscopes raise concerns regarding ERCP’s technical efficacy and safety in this vulnerable population, for whom conventional duodenoscopes are not recommended. Short case description: We report the case of a low-weight infant with short bowel syndrome under parenteral nutrition, who was referred for ERCP due to choledocholithiasis with progressive jaundice. We opted for an ultra-slim forward viewing gastroscope (5.4mm distal end outer diameter and 2.2mm working channel) with a needle knife sphincterotome (1.8mm outer sheath diameter). This allowed sphincterotomy with adequate gallstone removal and complete normalization of cholestasis parameters without associated complications. Discussion and conclusion: With this case we aimed to describe a previously unreported approach to a low-weight infant with gallstone disease requiring ERCP, which proved to be safe and effective.
- 30 November 2023
- Published by Indonesian Society of Pediatric Gastroenterology, Hepatology, and Nutrition in Archives of Pediatric Gastroenterology, Hepatology, and Nutrition
- Vol. 2 (4) , 24-9
Open AccessEndoscopic Retrograde Cholangiopancreatography with an Ultra-Slim Forward-Viewing Gastroscope in a 3.8 kg Infant: A Case-Report
Background: Experience with pediatric endoscopic retrograde cholangiopancreatography (ERCP), particularly in infants, is limited. The lower incidence of biliopancreatic disorders in infants and the discontinuation of pediatric duodenoscopes raise concerns regarding ERCP’s technical efficacy and safety in this vulnerable population, for whom conventional duodenoscopes are not recommended. Short case description: We report the case of a low-weight infant with short bowel syndrome under parenteral nutrition, who was referred for ERCP due to choledocholithiasis with progressive jaundice. We opted for an ultra-slim forward viewing gastroscope (5.4mm distal end outer diameter and 2.2mm working channel) with a needle knife sphincterotome (1.8mm outer sheath diameter). This allowed sphincterotomy with adequate gallstone removal and complete normalization of cholestasis parameters without associated complications. Discussion and conclusion: With this case we aimed to describe a previously unreported approach to a low-weight infant with gallstone disease requiring ERCP, which proved to be safe and effective.
- 21 November 2023
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 55 (1) , 435-443
Is Metformin Associated with a Lower Prevalence of Polyps, Adenomas, and Colorectal Carcinoma in Patients with Diabetes Mellitus?
Purpose Recent studies suggested a protective role of metformin in the development of colorectal cancer (CRC) and its precursors. We aimed to investigate if metformin was associated with a lower prevalence and number of colorectal polyps in diabetic patients and also adenomas, high-risk adenomas, and CRC. Methods Retrospective study on adult patients with diabetes mellitus followed in our hospital with a total colonoscopy between 2015 and 2019, treated with either metformin for > 5 years or other antidiabetic agent (control group). We assessed the number, size, and histopathology examination of proliferative lesions detected on colonoscopy. Results We included 401 patients aged 69 ± 9 years, 57% males, divided into two groups: treated with metformin (n = 260) and without (n = 141). The number of polyps detected was significantly lower in patients under metformin (p = 0.014). There was a nonsignificant trend towards lower polyp detection rates in the metformin compared to the control group both in unadjusted analysis (50% vs 60%, p = 0.058) and multivariable adjusted analysis (odds ratio [OR] 0.68, 95% confidence interval [CI] 0.43–1.09, p = 0.111). In the latter, we identified male gender (OR 2.24, 95%CI 1.44–3.49, p < 0.001), age (OR 1.35 for every 10 years, 95%CI 1.07–1.71, p = 0.012), glycated hemoglobin value (OR 1.20 for every 1% increase, 95%CI 1.06–1.37, p = 0.005), and hypertension (OR 1.76, 95%CI 1.01–3.08, p = 0.046) as factors associated with a higher prevalence of polyps. We saw no statistically significant differences regarding adenoma (p = 0.231), high-risk adenoma (p = 0.810), and CRC (p = 0.705) diagnoses between groups. Conclusion In our study, metformin was associated with less colorectal polyps in diabetic patients compared to other treatment modalities. We observed a nonsignificant trend towards lower polyp detection rates in the metformin group both in unadjusted and adjusted analyses.
- 21 November 2023
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 55 (1) , 435-443
Is Metformin Associated with a Lower Prevalence of Polyps, Adenomas, and Colorectal Carcinoma in Patients with Diabetes Mellitus?
Purpose Recent studies suggested a protective role of metformin in the development of colorectal cancer (CRC) and its precursors. We aimed to investigate if metformin was associated with a lower prevalence and number of colorectal polyps in diabetic patients and also adenomas, high-risk adenomas, and CRC. Methods Retrospective study on adult patients with diabetes mellitus followed in our hospital with a total colonoscopy between 2015 and 2019, treated with either metformin for > 5 years or other antidiabetic agent (control group). We assessed the number, size, and histopathology examination of proliferative lesions detected on colonoscopy. Results We included 401 patients aged 69 ± 9 years, 57% males, divided into two groups: treated with metformin (n = 260) and without (n = 141). The number of polyps detected was significantly lower in patients under metformin (p = 0.014). There was a nonsignificant trend towards lower polyp detection rates in the metformin compared to the control group both in unadjusted analysis (50% vs 60%, p = 0.058) and multivariable adjusted analysis (odds ratio [OR] 0.68, 95% confidence interval [CI] 0.43–1.09, p = 0.111). In the latter, we identified male gender (OR 2.24, 95%CI 1.44–3.49, p < 0.001), age (OR 1.35 for every 10 years, 95%CI 1.07–1.71, p = 0.012), glycated hemoglobin value (OR 1.20 for every 1% increase, 95%CI 1.06–1.37, p = 0.005), and hypertension (OR 1.76, 95%CI 1.01–3.08, p = 0.046) as factors associated with a higher prevalence of polyps. We saw no statistically significant differences regarding adenoma (p = 0.231), high-risk adenoma (p = 0.810), and CRC (p = 0.705) diagnoses between groups. Conclusion In our study, metformin was associated with less colorectal polyps in diabetic patients compared to other treatment modalities. We observed a nonsignificant trend towards lower polyp detection rates in the metformin group both in unadjusted and adjusted analyses.
- Open Access
- 15 November 2023
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 31 (5) , 325-337
COVID-19 Vaccination in Liver Cirrhosis: Safety and Immune and Clinical Responses
Introduction: Three years after the beginning of the SARS-CoV-2 pandemic, the safety and efficacy of COVID-19 vaccination in liver cirrhosis (LC) patients remain controversial. We aimed to study the safety, immunological, and clinical responses of LC patients to COVID-19 vaccination. Methods: Prospective multicentric study in adults with LC eligible for COVID-19 vaccination, without prior known infection. Patients were followed up until the timing of a booster dose, SARS-CoV-2 infection, or death. Spike-protein immunoglobulin G antibody titers for SARS-CoV-2 at 2 weeks, 3 months, and 6 months postvaccination were assessed. Antibody titers 200 BAU/mL at 3 months. Conclusion: COVID-19 vaccines in patients with LC were safe, without serious adverse events. The humoral and clinical responses were similar to the reported for the general population. Humoral response was adversely impacted by older age and adenovirus vector vaccines and unrelated to the liver disease severity.
- 15 November 2023
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 31 (5) , 325-337
Open AccessCOVID-19 Vaccination in Liver Cirrhosis: Safety and Immune and Clinical Responses
Introduction: Three years after the beginning of the SARS-CoV-2 pandemic, the safety and efficacy of COVID-19 vaccination in liver cirrhosis (LC) patients remain controversial. We aimed to study the safety, immunological, and clinical responses of LC patients to COVID-19 vaccination. Methods: Prospective multicentric study in adults with LC eligible for COVID-19 vaccination, without prior known infection. Patients were followed up until the timing of a booster dose, SARS-CoV-2 infection, or death. Spike-protein immunoglobulin G antibody titers for SARS-CoV-2 at 2 weeks, 3 months, and 6 months postvaccination were assessed. Antibody titers 200 BAU/mL at 3 months. Conclusion: COVID-19 vaccines in patients with LC were safe, without serious adverse events. The humoral and clinical responses were similar to the reported for the general population. Humoral response was adversely impacted by older age and adenovirus vector vaccines and unrelated to the liver disease severity.
- Open Access
- 12 October 2023
- Published by Springer Nature in Research Square
Is metformin associated with a lower prevalence of polyps, adenomas and colorectal carcinoma in patients with diabetes mellitus?
Purpose. Recent studies suggested a protective role of metformin in the development of colorectal cancer (CRC) and its precursors. We aimed to investigate if metformin was associated with a lower prevalence and number of colorectal polyps in diabetic patients and, secondarily, adenomas, high-risk adenomas and CRC.Methods. Retrospective study on adult patients with diabetes mellitus followed in our hospital with a total colonoscopy between 2015–2019, treated with either metformin for > 5 years or other antidiabetic agent (control group). We assessed the number, size and histology of proliferative lesions detected on colonoscopy.Results. We included 401 patients aged 69 ± 9 years, 57% males, divided in two groups: treated with metformin (n = 260) and without (n = 140). The number of polyps detected was significantly lower in patients under metformin (p = 0.014). There was a nonsignificant trend towards lower polyp detection rates in the metformin compared to the control group both in unadjusted analysis (50% vs 60%, p = 0.058) and adjusted analysis (odds ratio [OR] 0.68, 95% confidence interval [CI] 0.43–1.09, p = 0.111). In the latter we identified male gender (OR 2.24, 95%CI 1.44–3.49, p < 0.001), age (OR 1.35 for every 10 years, 95%CI 1.07–1.71, p = 0.012), glycated hemoglobin value (OR 1.20 for every 1% increase, 95%CI 1.06–1.37, p = 0.005) and hypertension (OR 1.76, 95%CI 1.01–3.08, p = 0.046) as factors associated with a higher prevalence of polyps. We saw no statistically significant differences regarding adenoma (p = 0.231), high-risk adenoma (p = 0.810) and CRC (p = 0.705) diagnoses between groups.Conclusion. In our study, metformin was associated with less colorectal polyps in diabetic patients compared to other treatment modalities. The polyp detection rates, although lower in the metformin group, had no statistically significant differences between groups both in unadjusted and adjusted analysis.
- 12 October 2023
- Published by Springer Nature in Research Square
Open AccessIs metformin associated with a lower prevalence of polyps, adenomas and colorectal carcinoma in patients with diabetes mellitus?
Purpose. Recent studies suggested a protective role of metformin in the development of colorectal cancer (CRC) and its precursors. We aimed to investigate if metformin was associated with a lower prevalence and number of colorectal polyps in diabetic patients and, secondarily, adenomas, high-risk adenomas and CRC.Methods. Retrospective study on adult patients with diabetes mellitus followed in our hospital with a total colonoscopy between 2015–2019, treated with either metformin for > 5 years or other antidiabetic agent (control group). We assessed the number, size and histology of proliferative lesions detected on colonoscopy.Results. We included 401 patients aged 69 ± 9 years, 57% males, divided in two groups: treated with metformin (n = 260) and without (n = 140). The number of polyps detected was significantly lower in patients under metformin (p = 0.014). There was a nonsignificant trend towards lower polyp detection rates in the metformin compared to the control group both in unadjusted analysis (50% vs 60%, p = 0.058) and adjusted analysis (odds ratio [OR] 0.68, 95% confidence interval [CI] 0.43–1.09, p = 0.111). In the latter we identified male gender (OR 2.24, 95%CI 1.44–3.49, p < 0.001), age (OR 1.35 for every 10 years, 95%CI 1.07–1.71, p = 0.012), glycated hemoglobin value (OR 1.20 for every 1% increase, 95%CI 1.06–1.37, p = 0.005) and hypertension (OR 1.76, 95%CI 1.01–3.08, p = 0.046) as factors associated with a higher prevalence of polyps. We saw no statistically significant differences regarding adenoma (p = 0.231), high-risk adenoma (p = 0.810) and CRC (p = 0.705) diagnoses between groups.Conclusion. In our study, metformin was associated with less colorectal polyps in diabetic patients compared to other treatment modalities. The polyp detection rates, although lower in the metformin group, had no statistically significant differences between groups both in unadjusted and adjusted analysis.
- Open Access
- 31 August 2021
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 34 (9) , 640-641
Gastrointestinal Symptoms and Liver Injury on Admission in a Hospitalised Population with COVID-19 Infection
Gastrointestinal Symptoms and Liver Injury on Admission in a Hospitalised Population with COVID-19 Infection
- 31 August 2021
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 34 (9) , 640-641
Open AccessGastrointestinal Symptoms and Liver Injury on Admission in a Hospitalised Population with COVID-19 Infection
Gastrointestinal Symptoms and Liver Injury on Admission in a Hospitalised Population with COVID-19 Infection
- 22 August 2017
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 52 (11) , 1278-1285
The lifestyle influence on alcoholic pancreatitis versus alcoholic liver disease: a case-control study
To evaluate the association of lifestyle with the development of alcoholic liver disease (ALD) or alcoholic pancreatitis (AlcP). A case-control study was conducted on 80 patients attending a tertiary university hospital, subdivided into three groups: ALD (n = 34), AlcP (n = 21) and a control (CT) group (n = 25) of alcohol abusers without clinical evidence of hepatic or pancreatic disease. Participants were interviewed regarding alcohol consumption, tobacco use and diet. A physical examination was concomitantly performed and we had access to their complementary investigation. We included 10 females and 70 males (mean age 57 ± 10 years). The pure amount of alcohol consumed by the ALD group was significantly higher than the AlcP group, regarding both daily (grams/day) and lifetime (kilograms) consumptions (p = .018 and p = .009, respectively); no statistically significant differences were seen with the CT group. We found no differences regarding the beverage type or drinking outside meals. Smoking was very common in every study group, with higher consumptions and a significantly higher prevalence of ever smokers in the AlcP group, in comparison with ALD and CT patients (p = .033 and p = .036, respectively). There were significant differences in the patients' eating habits before the onset of disease between groups (p < .001), with ALD subjects reporting a less abundant diet and AlcP a more abundant diet in the past; most of the controls had unchanged habits. We found differences in lifestyle between ALD and AlcP, not considered sufficient to explain the subjects' susceptibility to one disease or the other.
- 22 August 2017
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 52 (11) , 1278-1285
The lifestyle influence on alcoholic pancreatitis versus alcoholic liver disease: a case-control study
To evaluate the association of lifestyle with the development of alcoholic liver disease (ALD) or alcoholic pancreatitis (AlcP). A case-control study was conducted on 80 patients attending a tertiary university hospital, subdivided into three groups: ALD (n = 34), AlcP (n = 21) and a control (CT) group (n = 25) of alcohol abusers without clinical evidence of hepatic or pancreatic disease. Participants were interviewed regarding alcohol consumption, tobacco use and diet. A physical examination was concomitantly performed and we had access to their complementary investigation. We included 10 females and 70 males (mean age 57 ± 10 years). The pure amount of alcohol consumed by the ALD group was significantly higher than the AlcP group, regarding both daily (grams/day) and lifetime (kilograms) consumptions (p = .018 and p = .009, respectively); no statistically significant differences were seen with the CT group. We found no differences regarding the beverage type or drinking outside meals. Smoking was very common in every study group, with higher consumptions and a significantly higher prevalence of ever smokers in the AlcP group, in comparison with ALD and CT patients (p = .033 and p = .036, respectively). There were significant differences in the patients' eating habits before the onset of disease between groups (p < .001), with ALD subjects reporting a less abundant diet and AlcP a more abundant diet in the past; most of the controls had unchanged habits. We found differences in lifestyle between ALD and AlcP, not considered sufficient to explain the subjects' susceptibility to one disease or the other.